Regulated Water
Compare Stocks
5 / 10Stock Comparison
PCYO vs DHR vs TMO vs MSEX vs AWR
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Diagnostics & Research
Medical - Diagnostics & Research
Regulated Water
Regulated Water
PCYO vs DHR vs TMO vs MSEX vs AWR — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Regulated Water | Medical - Diagnostics & Research | Medical - Diagnostics & Research | Regulated Water | Regulated Water |
| Market Cap | $281M | $124.33B | $176.36B | $955M | $3.01B |
| Revenue (TTM) | $29M | $24.78B | $45.20B | $199M | $679M |
| Net Income (TTM) | $14M | $3.69B | $6.86B | $44M | $134M |
| Gross Margin | 58.9% | 60.7% | 39.4% | 33.3% | 44.6% |
| Operating Margin | 35.1% | 21.0% | 17.8% | 28.1% | 30.8% |
| Forward P/E | 21.6x | 20.8x | 19.1x | 20.1x | 20.7x |
| Total Debt | $7M | $18.42B | $40.85B | $419M | $943M |
| Cash & Equiv. | $22M | $4.62B | $9.86B | $3M | $19M |
PCYO vs DHR vs TMO vs MSEX vs AWR — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Pure Cycle Corporat… (PCYO) | 100 | 115.0 | +15.0% |
| Danaher Corporation (DHR) | 100 | 118.9 | +18.9% |
| Thermo Fisher Scien… (TMO) | 100 | 135.9 | +35.9% |
| Middlesex Water Com… (MSEX) | 100 | 75.8 | -24.2% |
| American States Wat… (AWR) | 100 | 93.7 | -6.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: PCYO vs DHR vs TMO vs MSEX vs AWR
Each card shows where this stock fits in a portfolio — not just who wins on paper.
PCYO carries the broadest edge in this set and is the clearest fit for sleep-well-at-night and valuation efficiency.
- Lower volatility, beta 0.79, Low D/E 4.8%, current ratio 2.72x
- PEG 1.54 vs DHR's 34.35
- Beta 0.79, current ratio 2.72x
- PEG 1.54 vs 2.70
Among these 5 stocks, DHR doesn't own a clear edge in any measured category.
TMO is the #2 pick in this set and the best alternative if long-term compounding is your priority.
- 229.1% 10Y total return vs DHR's 219.3%
- +16.8% vs MSEX's -12.8%
MSEX ranks third and is worth considering specifically for income & stability.
- Dividend streak 21 yrs, beta -0.12, yield 2.7%
- 2.7% yield, 21-year raise streak, vs AWR's 2.5%, (1 stock pays no dividend)
AWR is the clearest fit if your priority is growth exposure.
- Rev growth 10.5%, EPS growth 6.3%, 3Y rev CAGR 10.2%
- 10.5% revenue growth vs PCYO's -9.3%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 10.5% revenue growth vs PCYO's -9.3% | |
| Value | PEG 1.54 vs 2.70 | |
| Quality / Margins | 46.6% margin vs DHR's 14.9% | |
| Stability / Safety | Beta 0.79 vs TMO's 1.10, lower leverage | |
| Dividends | 2.7% yield, 21-year raise streak, vs AWR's 2.5%, (1 stock pays no dividend) | |
| Momentum (1Y) | +16.8% vs MSEX's -12.8% | |
| Efficiency (ROA) | 8.2% ROA vs MSEX's 3.2%, ROIC 4.7% vs 4.7% |
PCYO vs DHR vs TMO vs MSEX vs AWR — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
PCYO vs DHR vs TMO vs MSEX vs AWR — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
PCYO leads in 3 of 6 categories
DHR leads 0 • TMO leads 0 • MSEX leads 0 • AWR leads 0 • 3 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
PCYO leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
TMO is the larger business by revenue, generating $45.2B annually — 1533.7x PCYO's $29M. PCYO is the more profitable business, keeping 46.6% of every revenue dollar as net income compared to DHR's 14.9%. On growth, PCYO holds the edge at +58.8% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $29M | $24.8B | $45.2B | $199M | $679M |
| EBITDAEarnings before interest/tax | $13M | $7.2B | $10.5B | $81M | $259M |
| Net IncomeAfter-tax profit | $14M | $3.7B | $6.9B | $44M | $134M |
| Free Cash FlowCash after capex | -$2M | $5.3B | $6.7B | -$19M | -$34M |
| Gross MarginGross profit ÷ Revenue | +58.9% | +60.7% | +39.4% | +33.3% | +44.6% |
| Operating MarginEBIT ÷ Revenue | +35.1% | +21.0% | +17.8% | +28.1% | +30.8% |
| Net MarginNet income ÷ Revenue | +46.6% | +14.9% | +15.2% | +22.1% | +19.7% |
| FCF MarginFCF ÷ Revenue | -7.5% | +21.4% | +14.9% | -9.7% | -5.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | +58.8% | +3.7% | +6.2% | +10.0% | +14.3% |
| EPS Growth (YoY)Latest quarter vs prior year | +18.8% | +9.8% | +11.3% | -100.0% | +8.6% |
Valuation Metrics
Evenly matched — PCYO and TMO each lead in 2 of 7 comparable metrics.
Valuation Metrics
At 21.6x trailing earnings, PCYO trades at a 38% valuation discount to DHR's 34.9x P/E. Adjusting for growth (PEG ratio), PCYO offers better value at 1.54x vs DHR's 34.35x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $281M | $124.3B | $176.4B | $955M | $3.0B |
| Enterprise ValueMkt cap + debt − cash | $266M | $138.1B | $207.4B | $1.4B | $3.9B |
| Trailing P/EPrice ÷ TTM EPS | 21.63x | 34.85x | 26.75x | 21.78x | 22.80x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 20.82x | 19.11x | 20.12x | 20.71x |
| PEG RatioP/E ÷ EPS growth rate | 1.54x | 34.35x | 12.67x | 13.62x | 2.98x |
| EV / EBITDAEnterprise value multiple | 26.71x | 18.21x | 19.04x | 15.79x | 15.61x |
| Price / SalesMarket cap ÷ Revenue | 10.79x | 5.06x | 3.96x | 4.91x | 4.58x |
| Price / BookPrice ÷ Book value/share | 1.98x | 2.38x | 3.34x | 1.89x | 2.84x |
| Price / FCFMarket cap ÷ FCF | 76.23x | 23.64x | 28.02x | — | — |
Profitability & Efficiency
PCYO leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
TMO delivers a 13.2% return on equity — every $100 of shareholder capital generates $13 in annual profit, vs $7 for DHR. PCYO carries lower financial leverage with a 0.05x debt-to-equity ratio, signaling a more conservative balance sheet compared to AWR's 0.90x. On the Piotroski fundamental quality scale (0–9), DHR scores 7/9 vs MSEX's 4/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +9.3% | +7.1% | +13.2% | +9.1% | +13.1% |
| ROA (TTM)Return on assets | +8.2% | +4.5% | +6.4% | +3.2% | +6.7% |
| ROICReturn on invested capital | +4.7% | +5.9% | +7.5% | +4.7% | +8.0% |
| ROCEReturn on capital employed | +5.3% | +7.0% | +9.1% | +4.4% | +8.5% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 7 | 6 | 4 | 6 |
| Debt / EquityFinancial leverage | 0.05x | 0.35x | 0.76x | 0.85x | 0.90x |
| Net DebtTotal debt minus cash | -$15M | $13.8B | $31.0B | $416M | $924M |
| Cash & Equiv.Liquid assets | $22M | $4.6B | $9.9B | $3M | $19M |
| Total DebtShort + long-term debt | $7M | $18.4B | $40.9B | $419M | $943M |
| Interest CoverageEBIT ÷ Interest expense | 18.00x | 18.13x | 5.89x | 4.33x | 4.35x |
Total Returns (Dividends Reinvested)
PCYO leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in AWR five years ago would be worth $10,732 today (with dividends reinvested), compared to $7,158 for MSEX. Over the past 12 months, TMO leads with a +16.8% total return vs MSEX's -12.8%. The 3-year compound annual growth rate (CAGR) favors PCYO at 8.4% vs MSEX's -9.2% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +8.0% | -23.6% | -19.8% | +3.0% | +7.0% |
| 1-Year ReturnPast 12 months | +12.5% | -8.3% | +16.8% | -12.8% | -1.0% |
| 3-Year ReturnCumulative with dividends | +27.2% | -15.5% | -11.7% | -25.2% | -9.0% |
| 5-Year ReturnCumulative with dividends | -19.8% | -21.1% | +2.8% | -28.4% | +7.3% |
| 10-Year ReturnCumulative with dividends | +159.6% | +219.3% | +229.1% | +62.9% | +123.2% |
| CAGR (3Y)Annualised 3-year return | +8.4% | -5.5% | -4.0% | -9.2% | -3.1% |
Risk & Volatility
Evenly matched — PCYO and AWR each lead in 1 of 2 comparable metrics.
Risk & Volatility
AWR is the less volatile stock with a -0.17 beta — it tends to amplify market swings less than TMO's 1.10 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. PCYO currently trades 96.1% from its 52-week high vs DHR's 72.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.79x | 0.94x | 1.10x | -0.12x | -0.17x |
| 52-Week HighHighest price in past year | $12.15 | $242.80 | $643.99 | $62.18 | $82.94 |
| 52-Week LowLowest price in past year | $9.65 | $172.06 | $385.46 | $44.17 | $69.45 |
| % of 52W HighCurrent price vs 52-week peak | +96.1% | +72.3% | +73.7% | +82.7% | +92.6% |
| RSI (14)Momentum oscillator 0–100 | 57.9 | 33.0 | 43.1 | 44.1 | 46.4 |
| Avg Volume (50D)Average daily shares traded | 54K | 4.2M | 1.9M | 160K | 298K |
Analyst Outlook
Evenly matched — MSEX and AWR each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: PCYO as "Buy", DHR as "Buy", TMO as "Buy", MSEX as "Buy", AWR as "Hold". Consensus price targets imply 40.6% upside for DHR (target: $247) vs 4.1% for MSEX (target: $54). For income investors, MSEX offers the higher dividend yield at 2.67% vs TMO's 0.36%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy | Hold |
| Price TargetConsensus 12-month target | — | $247.00 | $654.67 | $53.50 | $89.50 |
| # AnalystsCovering analysts | 1 | 42 | 42 | 4 | 10 |
| Dividend YieldAnnual dividend ÷ price | — | +0.7% | +0.4% | +2.7% | +2.5% |
| Dividend StreakConsecutive years of raises | — | 1 | 8 | 21 | 24 |
| Dividend / ShareAnnual DPS | — | $1.23 | $1.69 | $1.37 | $1.93 |
| Buyback YieldShare repurchases ÷ mkt cap | +0.1% | +2.5% | +1.7% | 0.0% | 0.0% |
PCYO leads in 3 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 3 categories are tied.
PCYO vs DHR vs TMO vs MSEX vs AWR: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is PCYO or DHR or TMO or MSEX or AWR a better buy right now?
For growth investors, American States Water Company (AWR) is the stronger pick with 10.
5% revenue growth year-over-year, versus -9. 3% for Pure Cycle Corporation (PCYO). Pure Cycle Corporation (PCYO) offers the better valuation at 21. 6x trailing P/E, making it the more compelling value choice. Analysts rate Pure Cycle Corporation (PCYO) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — PCYO or DHR or TMO or MSEX or AWR?
On trailing P/E, Pure Cycle Corporation (PCYO) is the cheapest at 21.
6x versus Danaher Corporation at 34. 9x. On forward P/E, Thermo Fisher Scientific Inc. is actually cheaper at 19. 1x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: American States Water Company wins at 2. 70x versus Danaher Corporation's 34. 35x.
03Which is the better long-term investment — PCYO or DHR or TMO or MSEX or AWR?
Over the past 5 years, American States Water Company (AWR) delivered a total return of +7.
3%, compared to -28. 4% for Middlesex Water Company (MSEX). Over 10 years, the gap is even starker: TMO returned +229. 1% versus MSEX's +62. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — PCYO or DHR or TMO or MSEX or AWR?
By beta (market sensitivity over 5 years), American States Water Company (AWR) is the lower-risk stock at -0.
17β versus Thermo Fisher Scientific Inc. 's 1. 10β — meaning TMO is approximately -738% more volatile than AWR relative to the S&P 500. On balance sheet safety, Pure Cycle Corporation (PCYO) carries a lower debt/equity ratio of 5% versus 90% for American States Water Company — giving it more financial flexibility in a downturn.
05Which is growing faster — PCYO or DHR or TMO or MSEX or AWR?
By revenue growth (latest reported year), American States Water Company (AWR) is pulling ahead at 10.
5% versus -9. 3% for Pure Cycle Corporation (PCYO). On earnings-per-share growth, the picture is similar: Pure Cycle Corporation grew EPS 12. 5% year-over-year, compared to -4. 7% for Danaher Corporation. Over a 3-year CAGR, AWR leads at 10. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — PCYO or DHR or TMO or MSEX or AWR?
Pure Cycle Corporation (PCYO) is the more profitable company, earning 50.
3% net margin versus 14. 7% for Danaher Corporation — meaning it keeps 50. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AWR leads at 30. 9% versus 18. 2% for TMO. At the gross margin level — before operating expenses — PCYO leads at 61. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is PCYO or DHR or TMO or MSEX or AWR more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, American States Water Company (AWR) is the more undervalued stock at a PEG of 2. 70x versus Danaher Corporation's 34. 35x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Thermo Fisher Scientific Inc. (TMO) trades at 19. 1x forward P/E versus 20. 8x for Danaher Corporation — 1. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DHR: 40. 6% to $247. 00.
08Which pays a better dividend — PCYO or DHR or TMO or MSEX or AWR?
In this comparison, MSEX (2.
7% yield), AWR (2. 5% yield), DHR (0. 7% yield), TMO (0. 4% yield) pay a dividend. PCYO does not pay a meaningful dividend and should not be held primarily for income.
09Is PCYO or DHR or TMO or MSEX or AWR better for a retirement portfolio?
For long-horizon retirement investors, American States Water Company (AWR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.
17), 2. 5% yield, +123. 2% 10Y return). Both have compounded well over 10 years (AWR: +123. 2%, TMO: +229. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between PCYO and DHR and TMO and MSEX and AWR?
These companies operate in different sectors (PCYO (Utilities) and DHR (Healthcare) and TMO (Healthcare) and MSEX (Utilities) and AWR (Utilities)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
DHR, MSEX, AWR pay a dividend while PCYO, TMO do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.